In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β 2-agonist may be an alternative to conventional treatment strategies. We conducted a 52-week, double-blind ...

October 28, 2011 (Honolulu, Hawaii) — Two big clinical trials of mometasone furoate with formoterol (Dulera, Merck) found the combination safe and effective in improving the lung function of patients ...

Breztri becomes the first single-inhaler triple therapy for patients as young as 12 years ...

In double-blind, placebo-controlled trials, budesonide–formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β 2-agonist ...

This combination medication contains steroid and bronchodilator, prescribed for asthma in patients 12 years of age and older.

When used as needed, the combination of budesonide-formoterol was found to be superior to albuterol for the prevention of asthma exacerbations in patients with mild asthma. When used as needed, the ...

Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...

Please provide your email address to receive an email when new articles are posted on . The meta-analysis included 27 unique randomized controlled trials and 50,496 patients. Combinations improved ...

Please provide your email address to receive an email when new articles are posted on . Maintenance and reliever therapy using inhaled corticosteroids and formoterol was associated with lower risk for ...

The management of asthma has changed since the introduction of budesonide/formoterol (Symbicort ®) as both maintenance and reliever therapy (SMART). SMART and its effects on bronchial ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed the hybrid medicine budesonide/formoterol fumarate dihydrate (Teva Pharma B.V.) for the ...

Formoterol presents formulators and manufacturers in the asthma and chronic obstructive pulmonary disease marketplace many challenges. Formoterol is increasingly viewed as the long-acting β2-agonist ...